Souhaitez-vous accéder aux communiqués récents ?

WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In...

The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort   The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline...

ADELAIDE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016...

Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017Sufficient PFS events reached for data analysis of both cohorts of Phase 3 niraparib NOVA trial; data expected in Q2...

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne...

WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016...

U.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant submittedNiraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a...

WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...

WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S....

Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in JapanTESARO to receive up to $450 million in upfront and milestone payments, plus...